ReviewFrontiers in bioengineering and biotechnology2020
Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 107 citations in OpenAlex.
- Novel lipid and ascorbyl stearate biomimetic vancomycin-loaded nanostructured lipid carrier therapy for bacterial infections and sepsis.RSC advances · 2026Article
- Nanomaterial-Based Therapeutic Delivery: Integrating Redox Biology, Genetic Engineering, and Imaging-Guided Treatment.Antioxidants (Basel, Switzerland) · 2026Review
- Amphiphilic Macromolecular Dendritic Antioxidants with Surfaces Coated in Hybrid Phenolic Units That Provide Anti-Inflammatory Properties.ACS applied polymer materials · 2026Article
- Novel epigenetic and transcriptomic profiles of immune, inflammatory, and cellular transduction pathways are associated with chronic perceived stress in midlife women.Brain, behavior, & immunity - health · 2026Article
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Editorial: Pharmacological advancements of novel natural-based nanomedicines.Frontiers in pharmacology · 2026Article
- Engineering nanoparticles for macrophage reprogramming in chronic inflammatory diseases: current advances, challenges, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Advanced nanotherapies for precision treatment of inflammatory lung diseases.Bioactive materials · 2025Review
- Nano-antioxidants for neurodegenerative disorders: a scoping review.Discover nano · 2025Review
- Combating Reactive Oxygen Species (ROS) with Antioxidant Supramolecular Polymers.ACS applied materials & interfaces · 2025Article
- Nanocarbon-Driven Recovery of Mechano-Kinetic Properties of Injured Rat Gastrocnemius Muscle.International journal of molecular sciences · 2025Article
- Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology.Discover nano · 2025Review
- Nanoparticles with Antioxidant Activity.Antioxidants (Basel, Switzerland) · 2025Article
- Nanomaterials reshape the pulmonary mechanical microenvironment: novel therapeutic strategies for respiratory diseases.Frontiers in bioengineering and biotechnology · 2025Review
- How to assess antioxidant activity? Advances, limitations, and applications of in vitro, in vivo, and ex vivo approaches.Food production, processing and nutrition · 2025Review
- An Explicative Review on Nanotechnology-based Drug Delivery Systems for Alleviating Oxidative Stress-driven Pathologies.Current drug metabolism · 2025Review
- Intrinsically bioactive multifunctional Poly(citrate-curcumin) for rapid lung injury and MRSA infection therapy.Bioactive materials · 2024Article
- Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis.Discover nano · 2024Review
- Oral administration of Sophora Flavescens-derived exosomes-like nanovesicles carrying CX5461 ameliorates DSS-induced colitis in mice.Journal of nanobiotechnology · 2024Article
- ST2825, independent of MyD88, induces reactive oxygen species-dependent apoptosis in multiple myeloma cells.Biochemistry and biophysics reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS) are essential in regulating various physiological functions. However, overproduction of ROS is implicated in the pathogenesis of various inflammatory diseases. Antioxidant therapy has thus represented an effective strategy for the treatment of oxidative stress relevant inflammatory diseases. Conventional anti-oxidative agents showed limited
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.